التفاصيل البيبلوغرافية
| العنوان: |
Preemptive administration of human αβ T cell receptor-targeting monoclonal antibody GZ-αβTCR potently abrogates aggressive graft-versus-host disease in vivo. |
| المؤلفون: |
Blank, Gregor, Welker, Christian, Sipos, Bence, Sonntag, Katja, Müller, Friederike, Eckert, Franziska, Seitz, Christian, Nadalin, Silvio, LaCorcia, Gina, Königsrainer, Alfred, Snell, Daniel, Handgretinger, Rupert, Schilbach, Karin, Müller, Friederike, Königsrainer, Alfred |
| المصدر: |
Annals of Hematology; Nov2015, Vol. 94 Issue 11, p1907-1919, 13p |
| مصطلحات موضوعية: |
GRAFT versus host disease, T cell receptors, THERAPEUTIC use of monoclonal antibodies, HEMATOPOIETIC stem cell transplantation, IMMUNITY, THERAPEUTICS |
| مستخلص: |
GVHD, both acute and chronic, remains the major cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation. Thus, there is still a great need for therapeutic tools for the prevention and treatment of GVHD. Several biologics have shown promising results in salvage therapies but are attendant on an increased risk for opportunistic infections, lymphoproliferative disorders, and relapse. This is partly due to efficient T cell elimination that neither dissects alloreactive from non-alloreactive T cells nor considers functional and structural distinctiveness of pathogen- and malignancy-reactive γδ and iNKT T cells. A novel, humanized monoclonal antibody, GZ-αβTCR, specific for the human αβ T cell receptor, was evaluated in a xenogeneic GVHD model for its potential to prevent or ameliorate GVHD and prolong survival. We could show that GZ-αβTCR significantly attenuated clinical signs of GVHD and prolonged survival by preferential depletion of CD4 cells and the naïve T cell compartment, the trigger and driver of GVHD. In a regimen that included a preemptive dose, GZ-αβTCR treatment sufficiently abrogated GVHD. Importantly, GZ-αβTCR's specificity spared host cell-mediated immune competence of cell types other than αβT cells: namely γδT cells. GZ-αβTCR's outstanding capacity to prevent GVHD and ameliorate an ongoing GVHD while sparing immune cells other than αβT cells strongly recommends GZ-αβTCR for the prevention and treatment of acute GVHD in clinical settings. [ABSTRACT FROM AUTHOR] |
|
Copyright of Annals of Hematology is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
